WASHINGTON--(BUSINESS WIRE)--April 21, 2004--The Sarbanes-Oxley Act of 2002 was passed in the wake of Enron and other corporate accounting scandals to prevent ethics scandals and other governance problems from recurring and to rebuild public trust in corporate business and reporting practices. The new Act is dramatically altering the legal and compliance landscape for the pharmaceutical industry.
On May 13, 2004 Thomas Gallagher, Partner at Pepper Hamilton LLP, will give a featured presentation at IIR's second annual Sarbanes-Oxley and Compliance Programs for the Pharmaceutical Industry conference. Mr. Gallagher explains that, "Cooperation is important, but EFFECTIVE cooperation is a key factor to ensure success when faced with governmental scrutiny." In a perfect world, government investigators will reward compliant behavior and will investigate, prosecute and punish non-compliant behavior. In his featured presentation, Mr. Gallagher clarifies the government investigation process so that pharmaceutical companies can transform both their culture and compliance programs to ensure compliance.
Thomas M. Gallagher is currently a partner with Pepper Hamilton LLP and a former prosecutor in the criminal division of the U.S. Attorney's Office in the Eastern District of Pennsylvania and has led the investigation and prosecution of numerous complex, multi-defendant white collar criminal matters in a number of industries, including health care, insurance, financial services and defense. In 1999, Mr. Gallagher received the Director's Award from then-Attorney General Janet Reno for his work in investigating and prosecuting health care fraud cases. In 2003, he received the Chief Postal Inspector's Award, the agency's highest award, for his outstanding prosecution of health care professionals. Mr. Gallagher was an Assistant U.S. Attorney in Philadelphia from 1995 through 2003.
Other topics covered at the conference include:
-- ELI LILLY discusses the impact of Sarbanes-Oxley on governance and accounting issues
-- INTERNAL REVENUE SERVICE explores the relationship between SOX and IRS requirements relative to disclosure requirements, reconciliation of tax and financial reporting, restated earnings and record retention
-- NOVARTIS GROUP presents a case study on turning SOX from a bureaucratic to an added value initiative
-- PUBLIC COMPANY ACCOUNTING OVERSIGHT BOARD (PCAOB) discusses current initiatives and the outlook for the future
-- U.S. SECURITIES AND EXCHANGE COMMISSION outlines current enforcement actions in the financial fraud arena
-- PFIZER presents a case study on living in the SOX world-beyond 404
-- AXENTIS leverages efforts beyond Sarbanes-Oxley into an enterprise-wide governance, risk and compliance management approach
-- DELOITTE reviews using Sarbanes-Oxley as a bridge to better business performance
Conference attendees are able to receive CLE and CPE credits for attendance. For additional details visit www.iirusa.com/sox. To register for the 2nd Annual Sarbanes-Oxley and Compliance Programs for the Pharmaceutical Industry conference call IIR at (888) 670-8200, e-mail firstname.lastname@example.org, or go online www.iirusa.com/sox. Please mention the registration priority code: XWBWPR.
The Institute for International Research
U.S.: 888-670-8200 email@example.com/ www.iirusa.com/sox Please mention the registration priority code: XWBWPR